Cargando…
基于雌激素受体信号通路的肺癌靶向治疗研究进展
Increasing evidence indicates that estrogen promotes tumor growth in both estrogen target organs and non-target organs. Estrogen regulates cell proliferation and differentiation via two different receptors, estrogen receptors α and β (ERα and ERβ). In recent decades, with the clarification of the ER...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999620/ https://www.ncbi.nlm.nih.gov/pubmed/21924040 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.07 |
_version_ | 1783331454765236224 |
---|---|
collection | PubMed |
description | Increasing evidence indicates that estrogen promotes tumor growth in both estrogen target organs and non-target organs. Estrogen regulates cell proliferation and differentiation via two different receptors, estrogen receptors α and β (ERα and ERβ). In recent decades, with the clarification of the ERα-mediated signaling pathways in breast cancer, targeted therapy through these pathways have successfully been used in clinical application. Tamoxifen, the classic representative, is a selective estrogen receptor modulator (SERM). Along with the elucidation of the role of estrogen in the pathophysiology of lung cancer, targeted lung cancer treatment based on the ER signaling pathways is also gradually being applied and it could become an important part of the comprehensive treatment for lung cancer. |
format | Online Article Text |
id | pubmed-5999620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59996202018-07-06 基于雌激素受体信号通路的肺癌靶向治疗研究进展 Zhongguo Fei Ai Za Zhi 综述 Increasing evidence indicates that estrogen promotes tumor growth in both estrogen target organs and non-target organs. Estrogen regulates cell proliferation and differentiation via two different receptors, estrogen receptors α and β (ERα and ERβ). In recent decades, with the clarification of the ERα-mediated signaling pathways in breast cancer, targeted therapy through these pathways have successfully been used in clinical application. Tamoxifen, the classic representative, is a selective estrogen receptor modulator (SERM). Along with the elucidation of the role of estrogen in the pathophysiology of lung cancer, targeted lung cancer treatment based on the ER signaling pathways is also gradually being applied and it could become an important part of the comprehensive treatment for lung cancer. 中国肺癌杂志编辑部 2011-09-20 /pmc/articles/PMC5999620/ /pubmed/21924040 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.07 Text en 版权所有©《中国肺癌杂志》编辑部2011 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 综述 基于雌激素受体信号通路的肺癌靶向治疗研究进展 |
title | 基于雌激素受体信号通路的肺癌靶向治疗研究进展 |
title_full | 基于雌激素受体信号通路的肺癌靶向治疗研究进展 |
title_fullStr | 基于雌激素受体信号通路的肺癌靶向治疗研究进展 |
title_full_unstemmed | 基于雌激素受体信号通路的肺癌靶向治疗研究进展 |
title_short | 基于雌激素受体信号通路的肺癌靶向治疗研究进展 |
title_sort | 基于雌激素受体信号通路的肺癌靶向治疗研究进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999620/ https://www.ncbi.nlm.nih.gov/pubmed/21924040 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.07 |
work_keys_str_mv | AT jīyúcíjīsùshòutǐxìnhàotōnglùdefèiáibǎxiàngzhìliáoyánjiūjìnzhǎn AT jīyúcíjīsùshòutǐxìnhàotōnglùdefèiáibǎxiàngzhìliáoyánjiūjìnzhǎn AT jīyúcíjīsùshòutǐxìnhàotōnglùdefèiáibǎxiàngzhìliáoyánjiūjìnzhǎn AT jīyúcíjīsùshòutǐxìnhàotōnglùdefèiáibǎxiàngzhìliáoyánjiūjìnzhǎn AT jīyúcíjīsùshòutǐxìnhàotōnglùdefèiáibǎxiàngzhìliáoyánjiūjìnzhǎn |